Last reviewed · How we verify
Tumescent solution with dilute lidocaine and epinephrine
Tumescent solution with dilute lidocaine and epinephrine is a Small molecule drug developed by Total Definer Research Group. It is currently FDA-approved.
Tumescent solution with dilute lidocaine and epinephrine, marketed by Total Definer Research Group, holds a niche position in the local anesthetic market. The key composition patent expiring in 2028 provides a period of exclusivity, enhancing the company's competitive advantage. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Tumescent solution with dilute lidocaine and epinephrine |
|---|---|
| Sponsor | Total Definer Research Group |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study (NA)
- EFFECTS OF TRANEXAMIC ACID IN TUMESCENT SOLUTION FOR LIPOSUCTION PROCEDURES (PHASE4)
- A Comparison of Tumescence in Breast Reduction Surgery (PHASE4)
- Tumescent Lidocaine Maximum Safe mg/kg Dosage (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tumescent solution with dilute lidocaine and epinephrine CI brief — competitive landscape report
- Tumescent solution with dilute lidocaine and epinephrine updates RSS · CI watch RSS
- Total Definer Research Group portfolio CI